The diagnosis of cancer is challenging despite the availability of large number of biochemical and imaging investigations. Both MRI and MRS based on same magnetic resonance phenomenon but the technical difference between the methods lies in the use of magnetic field gradients. In MRI, magnetic field gradients are used to achieve spatial information in the form of images. However, in MRS homogeneous magnetic field is necessary to observe the chemical shift differences of biochemical's (metabolites) and therefore no magnetic field gradients are necessary during signal acquisition. For example, the water suppressed 1 H MR spectrum of malignant breast tissues at 1.5T showed a peak at 3.2 ppm corresponding to several choline-containing compounds (tCho) indicative of malignancy. With the advancements in coil technology and with the availability of high-field scanners, report on the observation of tCho has become more frequent in some benign and normal breast tissues also, questioning the diagnostic utility of in vivo MRS. In addition, tCho was observed in normal breast tissue of lactating women (2,4,5).
INTRODUCTION
The diagnosis of cancer is challenging despite the availability of large number of biochemical and imaging investigations. For example, the water suppressed 1 H MR spectrum of malignant breast tissues at 1.5T showed a peak at 3.2 ppm corresponding to several choline-containing compounds (tCho) indicative of malignancy. With the advancements in coil technology and with the availability of high-field scanners, report on the observation of tCho has become more frequent in some benign and normal breast tissues also, questioning the diagnostic utility of in vivo MRS. In addition, tCho was observed in normal breast tissue of lactating women (2,4,5).
These observations have made it essential to develop methods of absolute quantification of the concentration of tCho in malignant, normal and benign breast tissues and to determine the cut-off value for their differentiation. 
METHODS FOR QUANTIFICATION -DATA ANALYSIS
A method of referencing as well as spectral fitting is required in quantification procedures. Quantitation of MRS data consists of the following steps: (i) to determine the signal intensities (amplitude), (ii) applying corrections factors due to effects of relaxation, scalar coupling, several instrumental and pulse sequence dependent intensity distortions and imperfect localization, and (ii) converting signal amplitude in to concentration.
Model functions and estimation of parameters:
In MRS, the signal amplitude is proportional to the concentration of that metabolite. It 
METABOLITE CONCENTRATION IN BREAST CANCER
In brain, quantification of metabolites from in vivo MR spectra are routinely performed, however, in breast; it is difficult due to heterogeneous distribution of the glandular and adipose tissues. Haddadin et al. have recently reviewed methods of choline metabolite quantification and the role of high-field MRS in breast cancer (3). Two referencing strategies used for converting measured signal amplitudes into concentrations. As discussed earlier, corrections terms due to effects of relaxation, scalar coupling, several instrumental and pulse sequence dependent intensity distortions and imperfect localization need to be applied to the 5 data obtained. In the internal water referencing, the water peak from unsuppressed spectra from the same voxel is used as an internal reference. Bolan et al used TDFD method for fitting the breast MR spectra and used internal water referencing for determination of the concentration of tCho at 4T (6) . The advantage of TDFD is that it is easy to incorporate any line shape function and frequency-selective properties since the residuals are evaluated and minimized in FD. In general, the use of narrow frequency region is recommended while fitting small resonances like tCho in the presence of huge lipid peaks as in breast MRS.
Further, Bolan et al have worked out the corrected amplitude A of a peak by taking in to account several correction terms related to experimental conditions and the physical properties of each species (6) . As per the procedure described by Bolan et al (1), the corrected amplitude A´, is then given by with correction factors:
where, 'gain' is the receiver gain, B 1 is the local amplitude of the excitation radiofrequency field, TR is the pulse repetition time, TE is the echo time, f gain receiver correction factor, necessary if receiver gain is different in suppressed and unsuppressed acquisitions. f coil coil receive efficiency factor calculated by assuming the transmit and receive efficiencies equal. In the external referencing scheme, the in vivo concentration of tCho is determined and compared to a measurement from an external phantom of known concentration. Bolan et al have worked out that the corrected signal amplitude A´ of a resonance is proportional to the number of nuclei n in the sample and is given by n = κ sys A´ (6). The system constant κ sys (with units' mol/au) accounts for the system specific hardware and software. The value of κ sys is calculated in separate calibration experiments with a phantom of known concentration and measurable relaxation properties. The externally referenced concentration of tCho can then be expressed in molal units (mol/kg) as where ρ water is the water density, and V is the voxel volume. To compare the internal and external methods, the tissue water density was assumed to be 1 kg/L. The volume V is the entire voxel volume, ignoring the effect of partial volume from adipose tissue (6) . The values determined by using the internal and external water referencing methods can then be compared and it was reported that both the methods are highly correlated, although the external method gave somewhat lower values (6).
The advantages of internal referencing is that it is simpler compared to the external referencing method. It automatically corrects for several experimental factors like coil transmit and receive efficiency, voxel size, and compartmentalization with adipose tissue.
However, its drawbacks include that it is sensitive to changes in T 2 and water characteristics, which is not the case with the externally referencing method. It is known that breast water content varies under normal physiological conditions and during chemotherapy. This effect can be minimized by accounting for water T2 variations in the quantification method, and by performing externally-referenced quantification of the water content as a control (6) .
Some researchers (8-10) have used a semi-quantitative method of estimating tCho by calculating the signal-to-noise ratio (SNR). ChoSNR is measured using the peak height 8 (intensity) of tCho signal and the intensity of noise from off-resonance region of the MR spectrum using the formula ChoSNR = amplitude of Cho resonance/RMS amplitude of noise.
Application of in vivo quantitation of metabolites in breast cancer studies (a) Differentiation of malignant, benign and normal breast tissues
The quantification of metabolites opened up many applications in clinical settings, for example, differentiation of malignant, benign and normal breast tissues can be carried out using cutoff values. Initially W-F ratio was used for this purpose and malignant lesions showed high W-F ratio compared to normal breast tissues (11) . From the un-suppressed spectra, W-F ratio calculated using the respective peak areas. However, W-F ratio showed significant overlap between malignant with benign lesions thus limiting its usefulness in the differential diagnosis (11) . In such cases, determination of absolute concentration will be more useful. Few groups have been working on the method for absolute determination of tCho as per the procedures described above. The reported concentration of tCho in breast cancer patients is in the range of 0.7-2.1 mM using external referencing method (12) . Using Several studies also reported the use of ChoSNR to differentiate malignant from benign lesions and a value of 2 and above was reported to be consistent with malignancy (8) (9) (10) . A ChoSNR of > 3.2 was reported for diagnosis of malignant lesions using multi-voxel MRS (15) . However, the SNR approach has some limitations in that noise is affected by factors related to instrument, patient movement, etc. However, the advantage of multi-voxel technique is that it provides a tool to monitor the changes in ChoSNR simultaneously from the tumor area as well as from normal portion of the breast. Recently, the use of tCho peak integral for differentiation of malignant and non-malignant breast tissues was reported using SV MRS (16).
(b) Monitoring tumor response to therapy
The determination of concentration of in vivo metabolites is also useful to monitor the tumor response to therapy to identify responders from non-responders so that appropriate patient management can be initiated. The parameter W-F ratio has been used in monitoring the tumor response to therapy in breast cancer patients (17) with reduction of W-F value observed after therapy in responders. Other parameters like lesion T 2 and tumor volume also have been used in predicting the therapeutic response (18) . Further, in patients who showed reduction in tumor size, a significant reduction or absence of tCho peak after III or VI NACT was reported (4). The potential of ChoSNR and tumor volume in the assessment of tumor response by sequential MRSI and conventional MRI was also reported (19) . A change in the absolute concentration of tCho was observed within 24 hours of administering chemotherapy that correlated positively to the lesion size changes (13) . Work in our laboratory on the tumor response of breast cancer patients using absolute concentration of tCho revealed that changes occur as early as after I NACT in responders compared to non-responders (14) . Another group reported changes in the concentration of tCho and tumor size during NACT between patients who achieved pathologic complete response with those who did not using integral values of the tCho peak (20).
METHODS OF QUANTIFICATION IN PROSTATE CANCER
The proton MR spectrum ( This was lower than the mean value observed for normal PZ (42.2 ± 5.8 µmol/g wet weight)
and CG (64.5 ± 13.6 µmol/g wet weight).
Generally, the changes in Cit and Cho are quantified by using ratios of metabolites using a scoring systems that takes into account not only the ratio but also changes in choline (choline/creatine ratio) and polyamines (22) . However, the limitations associated with measuring changes in these metabolites are the inability to accurately quantify changes in these metabolites due to overlap of individual resonances, problems with lipid contamination, and differential T1 saturation effects. Several researchers used metabolite ratios and showed that ratios that are 2-3 standard deviations (SD) above the mean value can be used to identify cancer (21, 22) . It was shown that voxels in which the [(Cho+Cr)/Cit] is at least 2 SD above the average ratio may represent possible cancer, while if the ratio is more than 3 SD above the average value, then those voxels are considered to be suggestive of cancer [22] . However, there is no standard cut-off value of the metabolite ratio that can be used to determine the presence of malignancy of the prostate, and there may also be individual variability among patients. has also been reported (22) . These results indicate the potential of the semi-quantitative parameter (metabolite ratio) in the noninvasive assessment of prostate cancer aggressiveness.
The metabolite ratios has been shown to be useful parameter in the radiation treatment plan to optimize radiation dose selectively to regions of prostate cancer using either intensity modulated radiotherapy (IMRT) or brachytherapy (22) ; however, this is not being followed in routine clinical practice. Further, the ratios are used to discriminate residual or recurrent prostate cancer from residual benign tissue and atrophic/necrotic tissue after cryosurgery, hormone deprivation therapy, and radiation therapy (22) .
SUMMARY
In this presentation, the following were discussed: i. differentiation of malignant, benign and normal tissues,
ii. its role in monitoring the tumor response to therapy,
